AtheroGenics' CEO to Present Company Update
at SG Cowen 21st Annual Health Care Conference
ATLANTA, March 8 /PRNewswire/ -- AtheroGenics, Inc. (Nasdaq: AGIX - news), an emerging
pharmaceutical company, announced today that Russell M. Medford, M.D., Ph.D., president and chief
executive officer of the company, will present a company overview at the SG Cowen 21st Annual Health
Care Conference, being held at the Boston Marriott Copley Place on Thursday, March 15, 2001.
AtheroGenics will present two 45-minute back-to-back presentations from 1:15 to 3:00 p.m.
AtheroGenics, Inc., based in Atlanta, Ga., is focused on the discovery, development and
commercialization of novel drugs for the treatment of chronic inflammatory diseases such as heart disease
(atherosclerosis), rheumatoid arthritis and asthma. The company designed its lead product candidate,
AGI- 1067, to benefit patients with coronary artery disease, which is atherosclerosis of the blood vessels
of the heart. AtheroGenics recently completed dosing of AGI-1067 in a 300-patient Phase II clinical
study for the treatment of post-angioplasty restenosis with anticipated study results in the first half of
2001. In February 2001, the company filed an investigational new drug (IND) application with the U.S.
Food and Drug Administration for its second product candidate, AGIX-4207, a novel,
orally-administered drug for the treatment of rheumatoid arthritis. The filing is the first step in initiating a
Phase I clinical trial to assess the safety of AGIX-4207. For more information, please visit
www.atherogenics.com .
This press release may contain forward-looking statements made pursuant to the safe harbor provisions
of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain factors,
risks and uncertainties that may cause actual results, events and performance to differ materially from
those referred to in such statements. These risks include statements which address operating
performance, events or developments that we expect or anticipate will occur in the future, such as
projections about our future results of operations or our financial condition, our collaborative efforts with
Schering-Plough Corporation, the development of our product candidates, anticipated trends in our
business, and other such risks that could cause actual results to differ materially. These risks are
discussed in AtheroGenics' SEC filings, including the company's registration statement on Form S-1,
Registration No. 333-31140, filed with the Securities and Exchange Commission, and including but not
limited to the risks discussed in AtheroGenics' Form 10-Q reports for fiscal 2000, all of which are
incorporated by reference into this press release. These documents may also be examined at public
reference facilities maintained by the Securities and Exchange Commission or, to the extent filed via
EDGAR, accessed through the web site of the Securities and Exchange Commission
(http://www.sec.gov).
SOURCE: AtheroGenics, Inc. |
